Daxdilimab is an investigational medication given by injection under the skin (subcutaneous injection). It is being studied for treating moderate to severe discoid lupus erythematosus (DLE), which is a form of lupus that primarily affects the skin. The medication works by targeting the immune system to reduce inflammation and disease activity in people with DLE. This is a new treatment approach that aims to help control the symptoms and skin lesions associated with this condition.

Primary Discoid Lupus Erythematosus – A chronic autoimmune skin condition that causes coin-shaped (discoid) lesions on sun-exposed areas of the body, particularly the face, ears, and scalp. The lesions typically appear as red, inflamed patches that become thick and scaly, and may cause scarring and permanent hair loss in affected areas. The condition primarily affects the skin and doesn’t usually involve internal organs. Over time, the lesions can leave behind depressed areas of permanent scarring and skin color changes, with the center of older lesions often becoming lighter in color while the borders remain darker. The condition tends to worsen with sun exposure and may show periods of improvement and flare-ups.